help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on February 6, 2009, doi:10.1165/rcmb.2008-0446OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2008-0446OCv1
41/4/440    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Ozawa, Y.
Right arrow Articles by Chida, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ozawa, Y.
Right arrow Articles by Chida, K.
American Journal of Respiratory Cell and Molecular Biology. Vol. 41, pp. 440-448, 2009
© 2009 American Thoracic Society
DOI: 10.1165/rcmb.2008-0446OC

Mucosal Vaccine Using CTL Epitope-Pulsed Dendritic Cell Confers Protection for Intracellular Pathogen

Yuichi Ozawa1, Takafumi Suda1, Toshi Nagata2, Dai Hashimoto1, Yutaro Nakamura1, Noriyuki Enomoto1, Naoki Inui1,3, Yukio Koide2, Hirotoshi Nakamura1 and Kingo Chida1

1 Second Division, Department of Internal Medicine, 2 Department of Microbiology and Immunology, and 3 Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan

Correspondence and requests for reprints should be addressed to Takafumi Suda, M.D., Ph.D., 1-20-1 Handayama, Hamamatsu, 431-3192, Japan. E-mail: suda{at}hama-med.ac.jp

Effective protective immunity against respiratory infections with intracellular pathogens requires pathogen-specific cytotoxic T cells (CTL) in the lung. However, vaccines that induce pathogen-specific CTL in the lung are poorly explored. Dendritic cells (DC) have increasingly been exploited as vaccines against infections. However, few studies have investigated the ability of mucosal DC vaccines to elicit protective CTL responses in the lung. Our objective was to develop an efficacious mucosal DC vaccine to generate protective CTL against respiratory infections with intracellular pathogens. Bone marrow–derived DC (BM-DC) pulsed with a single immunodominant CTL epitope, listeriolysin O (LLO) 91-99, of Listeria monocytogenes (LM) were intratracheally administered into mice. The frequency and function of epitope-specific CTL in mediastinal lymph nodes (MLN) and spleen were assessed for their ability to protect against LM infection. After intratracheal administration, lipopolysaccharide (LPS)-treated LLO 91-99–loaded BM-DC (LPS-LLO DC) more frequently migrated to MLN than LPS-untreated LLO 91-99–loaded BM-DC (LLO DC). Using tetrameric H2-Kd/LLO 91-99 peptide complex, specific CD8+ T cells were found in MLN as well as the spleen in LPS-LLO DC–immunized mice, but not in LLO-DC–immunized mice. Both MLN and spleen cells obtained from LPS-LLO DC–immunized mice produced large amounts of IFN-{gamma} in response to LLO 91-99 with high epitope-specific CTL activities. Vaccination with LPS-LLO DC, but not LLO DC, protected mice against lethal respiratory infection with LM. These data suggest that mucosal vaccination with LPS-treated immunodominant CTL epitope-loaded DC is a promising strategy for generating protective CTL against respiratory infections with intracellular pathogens.

Key Words: mucosal vaccine • Listeria monocytogenes • cytotoxic T cells • immunodominant epitope


CLINICAL RELEVANCE

This study showed that intratracheal injection of single immunodominant epitope-loaded dendritic cell (DC) confers protection against respiratory infections with intracellular pathogens. Thus, mucosal vaccination using cytotoxic T cell (CTL) epitope-loaded DC is a promising strategy for generating protective CTL against intracellular pathogens in the lung.

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2009 American Thoracic Society.
  Membership Renewal